By clicking “accept additional cookies”, you agree to cookies being stored on your device.
Cookies help us:
make it easier to find things on our site
analyse how our site is used
improve our marketing.
Functional
Always active
These essential cookies make the website work properly. They do things like remember your progress through a form, they always need to be on to ensure functionality of core parts of the website. These don't track your data or store anything personalized.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
These cookies are set by third party websites and do things like tracking the performance of our conversions.
Hearing loss is highly heterogeneous – in causation and pathology.
Likely to need a range of different therapies for different causes and different sites-of-lesion.
Diagnosis of the cause, or at least the site-of-lesion, will be important to stratify patients for clinical trials, then to select the best treatment for each person.
Genome sequencing may be useful in some cases but the vast majority of people with hearing loss have no genetic or molecular diagnosis.
Can we develop other tools for site-of-lesion?
Some types of pathology may be treatable, even reversible, while other cochlear pathologies may not be treatable. Useful to know which is which
About Prof Karen P Steel
Professor of Sensory Function, King’s College London, UK
Karen P Steel obtained her PhD from University College London followed by research posts in Munich, Germany, the MRC Institute of Hearing Research in Nottingham, the Wellcome Sanger Institute in Hinxton, and currently is Professor of Sensory Function at King’s College London. Trained as a mouse geneticist, her main goal is to understand deafness.
She uses genetics as a tool to understand the underlying molecular pathways, and her current focus is on progressive (age-related) hearing loss. Her group works with both mouse and human data, using the mouse for understanding the different pathophysiological mechanisms involved in hearing loss and human genomic data to establish the most common types of deafness in the population.
She was awarded the Brain Prize in 2012 and has served the research community as an elected member of Council of the Royal Society, elected President of the International Mammalian Genetics Society, and elected President of the Association for Research in Otolaryngology among many other roles.
Satellite event of the 58th Inner Ear Biology Meeting